Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
benfotiamine + donepezil
- Development stage
- Preclinical
- Lead developer
- Eisai
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Benfotiamine + donepezil is a combination therapy being investigated for the treatment of Alzheimer's disease. Benfotiamine is a synthetic derivative of thiamine (vitamin B1) with improved bioavailability, while donepezil is an acetylcholinesterase inhibitor. The combination has shown synergistic effects in delaying cognitive decline in patients with mild to moderate Alzheimer's disease, demonstrating better efficacy than donepezil monotherapy. The mechanism involves donepezil increasing acetylcholine levels in the brain while benfotiamine likely provides neuroprotective effects through thiamine-dependent pathways.
02
Targets
Acetylcholinesterase
Beyond the preview
Go deeper on benfotiamine + donepezil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on benfotiamine + donepezil.